Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study
The purpose of this study was to investigate clinical outcomes following stereotactic body radiotherapy (SBRT) for lung metastases as oligo-recurrence. From May 2003 to June 2014, records for 66 patients with 76 oligo-recurrences in the lungs treated with SBRT were retrospectively reviewed. Oligo-recurrence primary sites and patient numbers were as follows: lungs, 31; colorectal, 13; head and neck, 10; esophagus, 3; uterus, 3; and others, 6. The median SBRT dose was 50 Gy (range, 45–60 Gy) administered in a median of 5 (range, 5–9) fractions. All patients received SBRT, with no acute toxicity. Surviving patients had a median follow-up time of 36.5 months. The 3-year rates of local control, overall survival and disease-free survival were 90.6%, 76.0% and 53.7%, respectively. Longer disease-free interval from initial treatment to SBRT, and non-colorectal cancer were both associated with favorable outcomes. Disease progression after SBRT occurred in 31 patients, most with distant metastases (n = 24) [among whom, 87.5% (n = 21) had new lung metastases]. Among these 21 patients, 12 were judged as having a second oligo-recurrence. Additional SBRT was performed for these 12 patients, and all 12 tumors were controlled without disease progression. Three patients (4.5%) developed Grade 2 radiation pneumonitis. No other late adverse events of Grade ≥2 were identified. Thus, SBRT for oligo-recurrence achieved acceptable tumor control, with additional SBRT also effective for selected patients with a second oligo-recurrence after primary SBRT..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Journal of radiation research - 57(2016), 1, Seite 55-61 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aoki, Masahiko [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1093/jrr/rrv063 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1967600198 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1967600198 | ||
| 003 | DE-627 | ||
| 005 | 20220216153239.0 | ||
| 007 | tu | ||
| 008 | 160206s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jrr/rrv063 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1967600198 | ||
| 035 | |a (DE-599)GBVOLC1967600198 | ||
| 035 | |a (PRQ)c885-2199d8813623233e469b2d1552214d9431a6e92bb89d940edb498a5fac6c74923 | ||
| 035 | |a (KEY)0076070620160000057000100055stereotacticbodyradiotherapyforlungmetastasesasoli | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ZDB |
| 084 | |a 44.64 |2 bkl | ||
| 100 | 1 | |a Aoki, Masahiko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a The purpose of this study was to investigate clinical outcomes following stereotactic body radiotherapy (SBRT) for lung metastases as oligo-recurrence. From May 2003 to June 2014, records for 66 patients with 76 oligo-recurrences in the lungs treated with SBRT were retrospectively reviewed. Oligo-recurrence primary sites and patient numbers were as follows: lungs, 31; colorectal, 13; head and neck, 10; esophagus, 3; uterus, 3; and others, 6. The median SBRT dose was 50 Gy (range, 45–60 Gy) administered in a median of 5 (range, 5–9) fractions. All patients received SBRT, with no acute toxicity. Surviving patients had a median follow-up time of 36.5 months. The 3-year rates of local control, overall survival and disease-free survival were 90.6%, 76.0% and 53.7%, respectively. Longer disease-free interval from initial treatment to SBRT, and non-colorectal cancer were both associated with favorable outcomes. Disease progression after SBRT occurred in 31 patients, most with distant metastases (n = 24) [among whom, 87.5% (n = 21) had new lung metastases]. Among these 21 patients, 12 were judged as having a second oligo-recurrence. Additional SBRT was performed for these 12 patients, and all 12 tumors were controlled without disease progression. Three patients (4.5%) developed Grade 2 radiation pneumonitis. No other late adverse events of Grade ≥2 were identified. Thus, SBRT for oligo-recurrence achieved acceptable tumor control, with additional SBRT also effective for selected patients with a second oligo-recurrence after primary SBRT. | ||
| 540 | |a Nutzungsrecht: © The Author 2015. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. 2015 | ||
| 540 | |a © The Author 2015. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. | ||
| 700 | 1 | |a Hatayama, Yoshiomi |4 oth | |
| 700 | 1 | |a Kawaguchi, Hideo |4 oth | |
| 700 | 1 | |a Hirose, Katsumi |4 oth | |
| 700 | 1 | |a Sato, Mariko |4 oth | |
| 700 | 1 | |a Akimoto, Hiroyoshi |4 oth | |
| 700 | 1 | |a Miura, Hiroyuki |4 oth | |
| 700 | 1 | |a Ono, Shuichi |4 oth | |
| 700 | 1 | |a Takai, Yoshihiro |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of radiation research |d Chiba, 1960 |g 57(2016), 1, Seite 55-61 |w (DE-627)130398055 |w (DE-600)603983-2 |w (DE-576)015901394 |x 0449-3060 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2016 |g number:1 |g pages:55-61 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1093/jrr/rrv063 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26494115 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-CHE | ||
| 936 | b | k | |a 44.64 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 57 |j 2016 |e 1 |h 55-61 | ||